Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Escalation Study to Assess the Efficacy and Safety of Bradanicline in Subjects With Refractory Chronic Cough

NCT03622216 is registered in ClinicalTrials.gov with Attenua, Inc. as lead sponsor.

NCT NCT03622216
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03622216 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Escalation Study to Assess the Efficacy and Safety of Bradanicline in Subjects With Refractory Chronic Cough
Lead sponsor
Attenua, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 5, 2018
Completion date
May 22, 2019
Enrollment
46 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

chronic cough